Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort

Introduction: Lopinavir/ritonavir-based antiretroviral therapy (ART) is recommended for all HIV-infected children less than three years. However, little is known about its field implementation and effectiveness in West Africa. We assessed the 12-month response to lopinavir/ritonavir-based antiretrov...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2017-04, Vol.20 (2), p.E1
Main Authors: Amani-Bosse, Clarisse, Dahourou, Desire Lucien, Malateste, Karen, Amorissani-Folquet, Madeleine, Coulibaly, Malik, Dattez, Sophie, Emieme, Arlette, Barry, Mamadou, Rouzioux, Christine, N'gbeche, Sylvie, Yonaba, Caroline, Timite-Konan, Marguerite, Mea, Veronique, Ouedraogo, Sylvie, Blanche, Stephane, Meda, Nicolas, Seguin-Devaux, Carole, Leroy, Valeriane
Format: Article
Language:English
Subjects:
Analysis
Dosage and administration
Drug therapy
Health aspects
HIV patients
Lopinavir
Pediatric HIV infections
Ritonavir
Treatment outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Lopinavir/ritonavir-based antiretroviral therapy (ART) is recommended for all HIV-infected children less than three years. However, little is known about its field implementation and effectiveness in West Africa. We assessed the 12-month response to lopinavir/ritonavir-based antiretroviral therapy in a cohort of West African children treated before the age of two years. Methods: HIV-1-infected, ART-naive except for a prevention of mother-to-child transmission (PMTCT), tuberculosis-free, and less than two years of age children with parent's consent were enrolled in a 12-month prospective therapeutic cohort with lopinavir/ritonavir ART and cotrimoxazole prophylaxis in Ouagadougou and Abidjan. Virological suppression (VS) at 12 months (viral load [VL]
ISSN:1758-2652
1758-2652
DOI:10.7448/IAS.20.1.21362